MDT

96.9

+0.19%↑

A

137.41

-1.57%↓

VEEV

219.27

-1.3%↓

HQY

85.36

+0.4%↑

NEOG

9.46

+2.49%↑

MDT

96.9

+0.19%↑

A

137.41

-1.57%↓

VEEV

219.27

-1.3%↓

HQY

85.36

+0.4%↑

NEOG

9.46

+2.49%↑

MDT

96.9

+0.19%↑

A

137.41

-1.57%↓

VEEV

219.27

-1.3%↓

HQY

85.36

+0.4%↑

NEOG

9.46

+2.49%↑

MDT

96.9

+0.19%↑

A

137.41

-1.57%↓

VEEV

219.27

-1.3%↓

HQY

85.36

+0.4%↑

NEOG

9.46

+2.49%↑

MDT

96.9

+0.19%↑

A

137.41

-1.57%↓

VEEV

219.27

-1.3%↓

HQY

85.36

+0.4%↑

NEOG

9.46

+2.49%↑

Search

Certara Inc

Atvērts

SektorsVeselības aprūpe

9.51 9.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

9.19

Max

9.54

Galvenie mērījumi

By Trading Economics

Ienākumi

3.5M

1.5M

Pārdošana

46K

105M

P/E

Sektora vidējais

134.143

90.831

Peļņas marža

1.458

Darbinieki

1,487

EBITDA

-6.5M

23M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+27.34% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 25. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-384M

1.5B

Iepriekšējā atvēršanas cena

-0.31

Iepriekšējā slēgšanas cena

9.51

Ziņu noskaņojums

By Acuity

50%

50%

170 / 361 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Certara Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. janv. 16:17 UTC

Iegādes, apvienošanās, pārņemšana

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

2026. g. 19. janv. 23:50 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

2026. g. 19. janv. 23:42 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 19. janv. 22:29 UTC

Tirgus saruna

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

2026. g. 19. janv. 22:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 19. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 19. janv. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 19. janv. 17:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 19. janv. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 19. janv. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 19. janv. 17:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 19. janv. 17:09 UTC

Tirgus saruna

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

2026. g. 19. janv. 16:18 UTC

Tirgus saruna

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

2026. g. 19. janv. 16:12 UTC

Tirgus saruna

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

2026. g. 19. janv. 16:06 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

2026. g. 19. janv. 16:04 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

2026. g. 19. janv. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

LVMH, CTG Duty-Free Also Entered Into a MoU

2026. g. 19. janv. 16:02 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Subscription to Be Made Upon Completion of Transaction

2026. g. 19. janv. 16:00 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

2026. g. 19. janv. 16:00 UTC

Tirgus saruna

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

2026. g. 19. janv. 15:58 UTC

Iegādes, apvienošanās, pārņemšana

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

2026. g. 19. janv. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

2026. g. 19. janv. 15:57 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Proceeds of Transaction Will Be Paid in Cash

2026. g. 19. janv. 15:56 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

2026. g. 19. janv. 15:53 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

2026. g. 19. janv. 15:52 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

2026. g. 19. janv. 15:51 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

2026. g. 19. janv. 15:39 UTC

Tirgus saruna

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

2026. g. 19. janv. 15:37 UTC

Tirgus saruna

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Salīdzinājums

Cenas izmaiņa

Certara Inc Prognoze

Cenas mērķis

By TipRanks

27.34% augšup

Prognoze 12 mēnešiem

Vidējais 12.11 USD  27.34%

Augstākais 16 USD

Zemākais 9 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Certara Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

7

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

11.27 / 12.79Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Strong Bullish Evidence

Noskaņojums

By Acuity

170 / 361 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat